Association Between Gender-affirming Hormone Therapy and Measures of Glucose Metabolism: A Longitudinal Study
Authors' conclusion
Though the within-transgender cohort data suggest an increase in the levels of FG and HbA1c following feminizing GAHT initiation, these changes were no longer evident when compared with the corresponding changes in cisgender referents. Based on these results, clinically important effects of GAHT on routine laboratory markers of glucose metabolism appear unlikely.
Study context
- Population
- Transmasculine (TM) and transfeminine (TF) persons and presumably cisgender persons (without any evidence of gender diversity) in three large integrated health systems
- Participants
- 2,148 / 1,679 / 28,036 / 32,548
- Exposure
- Transgender persons on gender-affirming hormone therapy (GAHT) vs presumably cisgender persons
- TFn = 2,148
- TMn = 1,679
- Cisgender malesn = 28,036reference
- Cisgender femalesn = 32,548reference
- Outcome
- Temporal changes in FG and HbA1c levels (linear mixed models; ratios-of-ratios)
- Follow-up
- Pre- vs post-GAHT
Methodological detailsthree large integrated health systems
- Three large integrated health systems
Main finding
As reported in the abstract
Ratio-of-ratios (FG)
1.05
95% CI 1.01–1.09
TF
Ratio-of-ratios (HbA1c)
1.03
95% CI 0.99–1.06
TF
- TM vs cisgender cohort members, ratios-of-ratios
- 0.99 to 1.00 range
Observational data: associations, not effects.
Further findings
Post-GAHT changes, transgender vs cisgender persons
- Ratio-of-ratios close to the null and without a discernable pattern
Original publication
Association Between Gender-affirming Hormone Therapy and Measures of Glucose Metabolism: A Longitudinal Study. J Clin Endocrinol Metab. Published 30 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →